The bio industry is one of the next 10 promising technologies!
It is regarded as a key industry in the 21st century that contributes to a healthy abundant life.

  • The 21st-century bioindustry has been recognized as a key industry that contributes to the health and abundance of humanity based on long-term research and understanding. In particular, microbiome-related biotechnology requires a high degree of expertise and is drawing great attention as it was selected as a next-generation promising technology among all industrial fields by the Science and World Economic Forum in 2014.

    Kobiolabs has been publishing a number of Korean and international patents and studies in various fields including microbiome analysis, probiotics, and microbiome treatment technology, receiving recognition for its global technological capabilities. In particular, our researchers (including me) have joined the International Human Microbiome Consortium (IHMC) to represent Korea.
  • We have collaborated with Data Analysis and Coordination Center for the U.S.’ Human Microbiome Project, and our microbiome analysis technology has received international recognition.

    We will continue striving to realize our research achievements with top experts in the fields into the valuable asset of society to ensure that everyone enjoys a healthy happy life.

    Thank you.
    • President & CEO

GwangPyo Ko, Sc.D.


GwangPyo began his career as a microbiologist, working in research for a number of years before finding a Kobiolabs. He has published more than 100 papers and patents on health and food environment such as microbiome. Since 2011, he has been a director of Center for Human and Environmental Microbiome(Seoul National University) and also a PI and board member of International Human Microbiome Consortium. Prior to joining Seoul National University as a professor of Environmental Health Microbiology, he conducted post-doctoral work from University of North Carolina Chapel Hill and served as a assistant professor at Dept. of Environmental Health from University of Texas Health Science Center afterwards. He earned a M.S. and Sc.D. in Environmental Health from Harvard University.

Cheolwon Park

Chief Operating Officer

Cheolwon joined Kobiolabs as COO in Feb 2018. He has more than 20 years of extensive experiences from drug discovery & development to business development in a pharmaceutical industry. He most recently served as Head of Portfolio & BD at Alvogen Asia Pacific and Head of R&D at Alvogen Korea. Prior to that, he worked at LG Life Sciences and CJ Cheiljedang. Cheolwon has his B.A. in Pharmacy and his M.S. in Medicinal Chemistry from Seoul National University.

Tae-Wook Nam, Ph.D.

Chief Technology Officer

Tae-Wook has been Chief Technology Officer since 2017 overseeing in-house research and development. Prior to his current appointment, he served as a Director of NGS Service Division at Macrogen, Inc. He was responsible for the entire laboratory activities of Macrogen's NGS and biochip services aimed for genome research. He holds a doctorate and master’s degree in microbiology from Seoul National University

Sungji Kim

Head of Pharmaceutical Development

Prior to joining Kobiolabs as Head of Pharmaceutical Development, he was a director of business development at Alvogen Korea where he led portfolio management, new product launch and various domestic and overseas partnering. He has 20 years of pharmaceutical industry experience in R&D and BD field with various companies from R&D driven big Korean conglomerates (LG Life Science & CJ Cheiljedang) to multinational company (Alvogen). He earned a M.S. in Medicinal Chemistry from Seoul National University.

  • Feb 2019

    Securing ₩4billion won investment
    (CJ Cheiljedang&Timewise investment)

  • May 2018

    Selected as a Research and Business Development (R&BD) project by the Ministry of Trade, Industry, and Energy

    Received the Ministry of Science and ICT Award

    Selected as a Military Service Business by the Ministry of National Defense

  • July 2017

    Registered as a participant in MIT-lTP

    Innovative Technology Development Project of the Small

    and Medium Business Administration

    July 2017

    Series A

    Securing ₩10 billion won investment

    (Atinum Investment, Company K, and Stonebridge)

    Selected as a core technology development business by the Ministry of Trade, Industry, and Energy

    June 2017

    Innovative Technology Development Project of the Small and Medium Business Administration

    Selected as a global technology innovation IP strategic development business by the Korea Intellectual Property Strategy Agency

  • September 2016

    Partnership MOU between Kobiolabs and CKD Bio

    Selected as an investment-linked business growth R&D support project by the Ministry of Science, ICT, and Future Planning

    July 2016

    Selected as an immunity mechanism control technology by the Ministry of Science, ICT, and Future Planning

    March 2016

    Series A

    Investment promotion (CKD start-up investment)

    Selected as an IP R&D strategic development business by Korea Intellectual Property Strategy Agency

  • September 2015

    Selected for the high value-added food technology development project by the Ministry of Agriculture, Food, and Rural Affairs

    August 2015

    Secured the investment of Seoul Techno Holdings Inc.

    Selected as an investment-linked mentoring business by the Small and Medium Business Administration

    Certified by the Ministry of Environment as a Virus Inspection Agency

    Selected as a venture business start-up support business by the Small and Medium Business Administration

    July 2015

    Technology transfer MOU with Seoul National University Industry–Academy Cooperation Foundation

    June 2015

    Selected as a Research Exchange and International Industry Development Support Business by the Ministry of Science, ICT, and Future Planning

    May 2015

    Established a Kobiolabs affiliated research institute

    (Center for Microbiome Therapeutics; approved by the Korea Industrial Technology Association)

    Selected as the Research Achievement Commercialization Support Project by the Ministry of Science, ICT, and Future Planning

  • November 2014

    Certified by Kibo Technology Fund as a venture business

    August 2014

    Founded Kobiolabs, Inc.


Business Philosophy

Management Goals

Human Resources
and Organization

  • Passion
  • Diversity and autonomy in the
    organization allow employees’ creativity
    and the realization of their passions.
  • Providing opportunities for happy life and realizing dreams, developing products for customers to enjoy happy healthy lives, and striving to provide high investment return for our investors.

Mission (3p)

Passion Persistence Partnership

Personnel and

- Our company guarantees diversity and autonomy
- Our company will strive to create an atmosphere where employees can exercise their creative thinking and passio


- To Provide a comfortable and fulfilling atmos-phere for our employees to develop their skills
- To develop useful products for the healty living of our clients
- To offer our best efforts and high returns for our investors

  • Company Logo

    The leaf in the logo symbolizes life and nature. The circle around the leaf represents the microbiome with beneficial interactions in the human body and the environment